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Antonio Giordano1,4 and Andrea Morrione1*   

Abstract
Background: Mesothelioma is an aggressive disease with limited therapeutic options. The growth factor progranulin
plays a critical role in several cancer models, where it regulates tumor initiation and progression. Recent data from
our laboratories have demonstrated that progranulin and its receptor, EphA2, constitute an oncogenic pathway in
bladder cancer by promoting motility, invasion and in vivo tumor formation. Progranulin and EphA2 are expressed in
mesothelioma cells but their mechanisms of action are not well defined. In addition, there are no data establishing
whether the progranulin/EphA2 axis is tumorigenic for mesothelioma cells.
Methods: The expression of progranulin in various mesothelioma cell lines derived from all major mesothelioma
subtypes was examined by western blots on cell lysates, conditioned media and ELISA assays. The biological roles of
progranulin, EphA2, EGFR, RYK and FAK were assessed in vitro by immunoblots, human phospho-RTK antibody arrays,
pharmacological (specific inhibitors) and genetic (siRNAs, shRNAs, CRISPR/Cas9) approaches, motility, invasion and
adhesion assays. In vivo tumorigenesis was determined by xenograft models. Focal adhesion turnover was evaluated biochemically using focal adhesion assembly/disassembly assays and immunofluorescence analysis with focal
adhesion-specific markers.
Results: In the present study we show that progranulin is upregulated in various mesothelioma cell lines covering
all mesothelioma subtypes and is an important regulator of motility, invasion, adhesion and in vivo tumor formation.
However, our results indicate that EphA2 is not the major functional receptor for progranulin in mesothelioma cells,
where progranulin activates a complex signaling network including EGFR and RYK. We further characterized progranulin mechanisms of action and demonstrated that progranulin, by modulating FAK activity, regulates the kinetic
of focal adhesion disassembly, a critical step for cell motility.
Conclusion: Collectively, our results highlight the complexity of progranulin oncogenic signaling in mesothelioma,
where progranulin modulate functional cross-talks between multiple RTKs, thereby suggesting the need for combinatorial therapeutic approaches to improve treatments of this aggressive disease.
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Background
Malignant mesothelioma (MM), is an aggressive tumor
with a median survival of 12 months [1]. A major fraction of mesothelioma cases is linked to asbestos exposure, with a long latency period of 20–50 years between
exposure and mesothelioma development [2]. As a consequence of asbestos ban in Europe and some other
countries in the’80 and’90, we are observing a decline
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in the percentage of mesothelioma patients who have
been exposed to asbestos [3, 4]. Indeed, asbestos-related
mesothelioma are mainly seen in older patients who were
exposed to asbestos before the introduction of the ban.
However, there is an increase in mesothelioma cases
not associated with asbestos exposure mostly affecting
younger patients. Around 12% of patients presenting
with asbestos-unrelated mesotheliomas carries germline
mutations in BRCA1-associated protein 1 (BAP1) or
other tumor suppressor genes [3, 4].
Multiple novel targets and pathways of interest have
been identified from genomic studies of MM [5]. However, in MM, mutations do not usually affect growth-regulating kinases as in many other tumor types, rather they
affect tumor suppressor genes, whose targeting is more
complex. In addition, there are no predictive biomarkers
of therapy response [5]. There are three major histologic
subtypes of MM, epithelioid, biphasic and sarcomatoid
with different prognosis [6]. However, a more detailed
subclassification and histologic/cytological characterization of MM might have prognostic and perhaps predictive value for MM [6, 7]. In spite of considerable work
done in recent years to develop immunotherapies and
biomarker-driven therapy to improve patient outcomes,
there is still an unmet need for the identification of novel
targets to improve therapy.
Progranulin is a pluripotent growth factor containing
7 and a half highly-conserved granulins [8] cleaved by
elastase and MMPs to produce granulin peptides A-G
and paragranulin (p) [9, 10]. Progranulin is implicated in
several human diseases including cancer, neurodegenerative diseases and rheumatoid arthritis [11–13]. We
have established that progranulin plays a critical role in
prostate [14–17] and bladder cancer by promoting tumor
cell motility and invasion [18–21], in vivo tumor growth
and sensitizing cancer cells to cisplatin treatment [22].
We recently provided a significant advance in the field
by identifying a functional membrane receptor for progranulin, EphA2 [23], and later demonstrated that the
progranulin/EphA2 is a critical oncogenic axis in bladder
cancer [24]. The Eph receptors constitute the largest family of receptor tyrosine-kinase (RTKs) and are important
regulators of development and disease [25–27]. EphA2
activation by its natural ligand ephrinA1 (canonical signaling) regulates cellular repulsion and adhesion, but the
role of EphA2 in cancer is more complex with data suggesting either pro- or anti-oncogenic functions [28]. For
example, in the presence of ephrinA1, EphA2 is dephosphorylated at S897 leading to inhibition of cancer cell
motility and invasion. Conversely, ephrinA1-independent
AKT or RSK activation (non-canonical signaling) evokes
EphA2 phosphorylation at S897 enhancing EphA2 oncogenic activity [29].
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Progranulin is expressed in mesothelioma cells and
constitutes a VEGF-independent angiogenic factor [30].
Significantly, EphA2 is expressed in MM where it is
either overexpressed, mutated or amplified [31]. Notably,
the role of EphA2 in MM is still controversial and data
suggest either a positive or negative role in modulating
MM transformation. EphA2 activation with the ligand
ephrinA1 inhibits growth of MM [32] indicating that
ephrinA1-dependent EphA2 action has likely a tumor
suppressive function in mesothelioma. On the contrary, transient EphA2 depletion by siRNA approaches
inhibited growth and haptotaxis of MM cells, but the
experimental conditions were not clearly defined [33].
However, there are no data connecting progranulin tumorigenic action with non-canonical (ephrinA1-independent) EphA2 activation in MM and therefore no evidence
that the progranulin/EphA2 axis might be activated and
constitute an oncogenic pathway in MM.
Here we demonstrated that progranulin is critical for
the regulation of motility, invasion, adhesion and in vivo
tumor growth of MM cells by modulating FAK activity and focal adhesion turnover (assembly/disassembly).
However, EphA2 is not the major signaling receptor for
progranulin in MM cells, where progranulin relies on
the activation of EGFR and RYK, suggesting that in MM
the progranulin axis modulates a complex network of
RTKs signaling, which might constitute novel targets for
therapy.

Materials and methods
Cell culture and reagents

MeT-5A, NCI-H2052, NCI-H2452, NCI-H28 and
MSTO-211H cells were provided by ATCC and cultured
in RPMI (Thermo Scientific, Waltham, MA, USA), supplemented with 10% FBS (R&D Systems, Minneapolis, MN, USA) and 1% L-glutamine (Thermo Scientific
Scientific).
The MEK1/2 inhibitor U0126, the FAK inhibitor
PF-573228, the EGFR inhibitor gefitinib and nocodazole
were from Cayman Chemicals (Ann Arbor, MI, USA)
and the AKT inhibitor AKTi VIII form Calbiochem (San
Diego, CA, USA). His-tag human recombinant progranulin was prepared as previously described [34].
Gene depletion and expression

Transient gene depletion was obtained by transfecting cells with ON-TARGET plus small interfering RNAs
(siRNA) from Dharmacon (Lafayette, CO, USA) targeting GRN (progranulin) (L-009285–00-0005), EphA2
(L-003116–00-0005), PTK2 (FAK) (L-003164–00-0005),
EphA7 (L-003119–00-0005), RYK (L-003174–00-0005)
or non-targeting control siRNA (D-001810–10-05), using
the Dharmafect transfection reagent according to the
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Manufacturer’s instruction. siRNAs targeting progranulin, PTK2 and EphA7 were used at the final concentration
of 25 nM, siRNAs specific for EphA2 and RYK at 50 nM.
MSTO-211H and NCI-H2052 cells with progranulin
or EphA2 knock-out were generated using CRISPR/Cas9
strategies as previously described [35]. The sgRNAs GGT
GGCCTTAACAGCAGGGC [36] and GAAGCGCGG
CATGGAGCTCC targeting GRN and EphA2 were used
respectively.
Stable gene silencing of RYK was achieved using RYKspecific short hairpin RNAs (shRNA) (V2LHS_31986 and
V3LHS_345296, Dharmacon) and non-targeting control
shRNA (RHS4346), cloned in a pGIPZ lentiviral vector
(Dharmacon). pGIPZ vectors were used to generate lentivirus and transduce cells as previously described [35].
To prepare GRN KO MSTO-211H cells with reconstituted expression of progranulin and progranulin overexpressing NCI-H2052 cells, cDNA coding for human
progranulin was cloned into the lentiviral vector pLenti
CMV Puro DEST as previously described [35]. Human
progranulin cDNA was amplified by PCR using Phusion
high-fidelity DNA polymerase (New England Biolabs,
Ipswich, MA, USA), the primer pair GRN fwd/GRN rev
(Supplementary table 1) and total cDNA derived from
MSTO-211H cells as DNA template. MSTO-211H-derived total cDNA was prepared by retrotranscribing 1 µg
of total RNA extracted from MSTO-211H cells using the
Applied Biosystems High-Capacity cDNA Reverse transcription kit (Thermo Fisher Scientific). pLenti CMV
Puro DEST containing the progranulin sequence was
used to prepare lentiviral particles and transduce cells as
previously described [35].
To reconstitute EphA2 expression in EphA2 KO
MSTO-211H cells, we used the retroviral plasmid
pCLXSN-EphA2-Flag, a gift from Jin Chen (Addgene
plasmid #102755, Addgene, Wartertown, MA, USA).
EphA2 mutants were generated using Phusion highfidelity DNA polymerase (New England Biolabs), the
primers reported in Supplementary table 1 and plasmid
pCLXSN-EphA2-Flag as DNA template. To generate retroviral particles expressing wild type or mutants EphA2,
HEK-293FT cells were transfected with the pMD2-G
envelope plasmid, the pUMVC packaging plasmid (a
gift of Bob Weinberg, Addgene plasmid #8449) and the
pCLXSN retroviral vectors containing the cDNA coding
for wild type or mutants EphA2. HEK-293FT-transfected
conditioned media supplemented with 8 µg/ml polybrene (Sigma-Aldrich) was used to transduce EphA2 KO
MSTO-211H cells as described [37, 38].

Glendale, AZ, USA). Serum-starved cells were seeded
in SFM in the upper chamber at a cell density of 3 × 104
(MSTO-211H cells) or of 2 × 104 (NCI-H2052 cells). The
lower chamber was filled with 5% FBS-supplemented
medium (MSTO-211H) or SFM with or without 50 nM
progranulin (NCI-H2052). After 30 h (MSTO-211H)
or 16 h (NCI-H2052), cells on the filter upper surface
were removed with a cotton swab while cells on the filter lower surface were fixed with ice-cold methanol,
stained with Coomassie Brilliant Blue and counted under
a DMi1 inverted microscope (Leica, Wetzlar, Germany).
Cell invasion through a three-dimensional extracellular
matrix was measured using inserts containing an 8 µm
pore-size membrane with a uniform layer of matrigel
matrix (Corning). Experiments were performed as
described for migration but cells were allowed to invade
for 40 h (MSTO-211H) or 24 h (NCI-H2052).

Migration and invasion assays

In vivo xenograft

Cell migration was assessed by transwell migration assays
using 8.0 µm pore polyester membrane inserts (Corning,

In vivo experiments were performed according to protocols approved by the Institutional Review Board of

Adhesion assay

For adhesion assay, 24-well plates were coated over-night
with 5 µg/ml plasma fibronectin (R&D Systems) in PBS,
a collagen coating solution (Sigma Aldrich, St. louis,
MO, USA) or 0.01% Poly-L-Lys (Cultrex Poly-L-Lysine,
R&D Systems), washed with PBS and blocked with 2%
BSA in PBS. 2% BSA-coated wells were used as a negative control. Serum-starved cells were detached, and conditioned media collected and aliquoted. Cells were then
resuspended in an aliquot of their respective conditioned
media supplemented with 2.5 µM Calcein AM fluorescent dye (Cayman Chemicals) and incubated at 37 °C
for 30 min. Cells were then centrifuged, resuspended in
another aliquot of conditioned medium and seeded at a
cell density of 0,15 × 106 cells/well on fibronectin-, collagen- or Poly-L-Lys-coated wells. Cells were allowed to
adhere for 30 min (MSTO-211H) or 20 min (NCI-H2052)
at 37 °C, 5% CO2. Fluoresce intensity at λex = 494 nm
and λem = 517 nm was then measured using a Victor5
plate reader (Perkin Elmer, Waltham, MA, USA). Plates
were then washed two (MSTO-211H) or three (NCIH2052) times with PBS and fluorescence intensity was
measured again. The fraction of cells that adhered to the
various substrates was determined dividing the fluorescence intensity recorded after plate wash by the fluorescence intensity measured before plate wash. Similarly, the
minimal fraction of cells that adhered to BSA was determined and used to normalize the data. Cell–cell adhesion
was assessed in a similar way, by seeding cells stained
with Calcein AM on parental, PGRN-overexpressing or
EphA2 KO NCI-H2052 cell monolayers.
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Thomas Jefferson University. Eight-to-twelve-weeks-old
Rag2-/- mice were subcutaneously implanted in the flank
with 4 × 106 MSTO-211H parental, GRN KO, and EphA2
KO cells. Tumor volumes were measured every twodays using a micro-caliper and the following formula:
V = a(b2/2). When tumors reached a volume of 1500
mm3, mice were sacrificed.
Immunoblot

Cell lysates were prepared using RIPA buffer (Thermo
Fisher Scientific) supplemented with halt protease and
phosphatase inhibitors cocktail (Thermo Fisher Scientific). The following primary antibodies were used
for immunoblot analysis: pEphA2 S897 (6347), EphA2
(6997), pAKT S473 (4060), pan-AKT (4691), pERK1/2
(4370), ERK1/2 (9102), pFAK Y397 (3285), FAK (8556),
pEGFR Y1068 (3777), EGFR (4267), and EphA7 (64,801)
from Cell Signaling Technology (Danvers, MA, USA),
progranulin (P-9182-35B, US Biologicals, Salem, MA,
USA), pEphA2 S901 (PA5-105,552, Thermo Scientific),
and GAPDH (sc-365062) (Santa Cruz Biotechnology,
Dallas, TX, USA). The following secondary antibodies
were used: anti-rabbit HRP-linked (7074) (Cell Signaling
Technology) and the antibodies from Santa Cruz Biotechnology mouse anti-rabbit IgG-HRP (sc-2357) and
m-IgGk BP-HRP (sc-516102).
Immunoblots were quantified using the ImageJ program and expressed as arbitrary units (AU).
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(44-624G) (Thermo Fisher Scientific) and the monoclonal anti-vinculin antibody clone hVIN-1 (NB-600–1293)
(Novus Biologicals, Centennial, CO, USA). Secondary
antibodies were goat-anti rabbit IgG (H + L) Alexa Fluor488 and goat anti mouse IgG (H + L) Alexa Fluor 555
(Thermo Fisher Scientific). F-actin was stained using the
Phalloidin-iFluor 488 reagent (Abcam, Cambridge, UK).
Nuclei were stained using the SlowFade Gold Antifade
Mountant with DAPI (Thermo Fisher Scientific). Images
were acquired using an Olympus IX81 fluorescent microscope (Olympus, Tokyo, Japan) equipped with a Retiga
6000 camera (QImaging, Surrey, Canada) and the Olympus cellSens program (Olympus).
RT‑PCR

RT-PCR was performed using the delta-CT method [39]
using β-actin as a housekeeping gene. Primers specific for
RYK and β-actin are reported in Supplementary Table 1.
Statistical analysis

Data are shown as mean ± the standard deviation (s.d.).
Statistical significance was determined by performing one-way ANOVA followed by Tukey’s post hoc test
at 95% confidence interval (CI) or the Student t-test. A
p-value < 0.05 was considered statistically significant.
In ELISA, migration, invasion and adhesion assays and
qPCR experiments samples were analyzed in triplicates.
In vitro experiments were repeated three times.

Enzyme‑linked immunosorbent assay

Results

Progranulin concentration was measured in cell conditioned media using the human progranulin quantikine
ELISA kit (R&D Systems) following the Manufacturer’s
instructions. Protein concentration was normalized to
total cell number.

Progranulin promotes AKT and MAPK activation
and EphA2 phosphorylation at S897 in mesothelioma cells

Phospho‑RTK array

Human phospho-RTK antibody arrays membranes (R&D
Systems) were incubated with 0.7 mg of cell lysates from
MSTO-211H or NCI-H2052 cells serum-starved for
24 h, untreated or stimulated with 10 nM progranulin for
15 min and processed according to the manufacturer’s
instructions.
The intensity of the dots was quantified using the
ImageJ program.
Immunofluorescence analysis

For immunofluorescence experiments cells were washed
with PBS, fixed with 4% PFA in PBS for 15 min, permeabilized with 0.1% triton X-100 in PBS for 10 min
and blocked with 2% BSA in PBS for 1 h at RT. Fixed
cells were incubated over-night at 4 °C with the following primary antibodies diluted in 2% BSA: pFAK (Y397)

To characterize the role of the progranulin/EphA2 axis in
mesothelioma, we initially analyzed the expression levels of progranulin in a panel of mesothelioma cell lines
representative of the three major histologic subtypes,
sarcomatoid (NCI-H2052, NCI-H2452), epithelioid
(NCI-H28) and biphasic (MSTO-211H). Progranulin
was upregulated in all mesothelioma cell lines as compared to immortalized cells derived from normal mesothelium (MeT-5A), with the highest expression levels in
NCI-H2452, NCI-H28 and MSTO-211H, as assessed by
immunoblot in cell lysates, conditioned media and ELISA
assay (Fig. 1A-B). We then investigated the expression
levels of EphA2 and its phosphorylation at S897 and
S901 [24]. All mesothelioma cell lines showed EphA2
phosphorylation at S897 above the level of MeT-5A
cells, with MSTO-211H cells showing the highest levels,
while EphA2 S901 phosphorylation was only detectable
in NCI-H2452 and MSTO-211H cells (Fig. 1C). For our
experiments we therefore focused on sarcomatoid and
biphasic cells, considering that epithelioid NCI-H28 cells
express very low levels of EphA2.
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Next, we analyzed the signaling pathways activated by
progranulin in mesothelioma cells. Progranulin stimulation
promoted the activation of the AKT and MAPK pathways,
with a more pronounced effect on the MAPK pathway in
NCI-H2052 and NCI-H2452, while the AKT pathway was
preferentially activated in MSTO-211H cells (Fig. 1D). These
results suggest that progranulin signaling might slightly differ in mesothelioma cells originated from different mesothelioma subtypes. We also confirmed that progranulin
promoted EphA2 phosphorylation at S897 in NCI-H2052,
NCI-H2452 and MSTO-211H cells (Fig. 1D and Supplementary Fig. 4A). To assess whether AKT and ERK signaling was depending on endogenous progranulin, we used
siRNA strategies and transiently depleted endogenous progranulin in MSTO-211H cells, which express the highest
levels and show strong serine-phosphorylation of EphA2
(Fig. 1A-C). We achieved significant progranulin depletion, which was associated with a strong inhibition of AKT
activation (Fig. 1E and Supplementary Fig. 4B), confirming
therefore that AKT activation is, at least in part, dependent
on progranulin autocrine signaling in these cells. To confirm these data, we generated MSTO-211H cells with GRN
gene deletion by CRISPR/Cas9 approaches. GRN deleted
cells showed increased levels of pAKT and pEphA2 S897
and decreased levels of pERK1/2 when compared to parental cells (Fig. 1F, left panel, and Supplementary Fig. 4C). The
increased activation of AKT and EphA2 in GRN KO cells
was unexpected and suggest that upon progranulin deletion AKT and EphA2 activation might be sustained by compensatory mechanisms. Significantly, restoring progranulin
expression in GRN KO cells further increased the levels of
pAKT and pEphA2 S897 and restored basal activation of
ERK1/2 observed in parental MSTO-211H cells, thereby
confirming a role for progranulin in modulating the activation of the AKT and MAPK pathways in MSTO-211H cells
(Fig. 1F, left panel, and Supplementary Fig. 4C). To complement the GRN deletion data, we overexpressed progranulin
in NCI-H2052 cells, which express low levels of endogenous
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progranulin (Fig. 1A-B) and tested AKT and MAPK activation. Progranulin-overexpressing cells showed increased
pERK1/2 and pEphA2 S897 levels when compared to
parental NCI-H2052 (Fig. 1F, right panel, and Supplementary Fig. 4C), further suggesting the role of progranulin in
promoting the activation of MAPK and EphA2. Finally, we
demonstrated that progranulin-induced EphA2 phosphorylation at S897 in MSTO-211H and NCI-H2052 cells was
mediated by progranulin-dependent ERK1/2 activation,
and to a lesser extent of AKT activation, as demonstrated
by using specific pharmacological inhibitors of the AKT and
MAPK pathways (Fig. 1G).
Progranulin modulates cell motility, adhesion and in vivo
tumor growth

To further decipher the contribution of EphA2 in modulating the progranulin axis in mesothelioma, we generated MSTO-211H and NCI-H2052 cells with genetic
deletion of EphA2 by CRISPR/Cas9 technology (Supplementary Fig. 1A-B) and compared the ability of GRNand EphA2-KO cells to migrate and invade through
matrigel [14, 18–20, 22, 24].
GRN KO MSTO-211H cells showed significantly
reduced migratory ability as compared to parental
MSTO-211H cells (Fig. 2A). Notably, progranulin expression in GRN KO cells restored their migratory capacity (Fig. 2A) indicating a specific role of progranulin in
modulating MSTO-211H cells motility. Interestingly,
parental and EphA2 KO MSTO-211H cells migrated to a
similar extent, suggesting that EphA2 loss did not significantly affect MSTO-211H cell motility (Fig. 2B). In addition, GRN KO MSTO-211H cells showed significantly
impaired invasive capacity through matrigel as compared
to MSTO-211H cells, whereas parental and EphA2 KO
MSTO-211H cells were similar in their invasive abilities
(Fig. 2C). These results strongly suggest that progranulin regulates MSTO-211H cell motility independently
of EphA2 activation. Based on these results suggesting a

(See figure on next page.)
Fig. 1 Progranulin promotes AKT and MAPK activation in mesothelioma cells. A Progranulin (PGRN) protein levels were analyzed by immunoblot in
cell lysates and media conditioned from MeT-5A, NCI-H2052, NCI-H2452, NCI-H28 and MSTO-211H cells. B Progranulin levels in media conditioned
from MeT-5A, NCI-H2052, NCI-H2452, NCI-H28 and MSTO-211H cells was measured by ELISA assay. N = 3, ± SD, ** p < 0.01, *** p < 0.001. C Levels
of total and phosphorylated EphA2 (S897 and S901) were analyzed by immunoblot in cell lysates derived from MeT-5A, NCI-H2052, NCI-H2452,
NCI-H28 and MSTO-211H cells serum-starved for 24 h. D Levels of total and phosphorylated EphA2 (S897), AKT and ERK1/2 were assessed by
immunoblot in NCI-H2052, NCI-H2452 and MSTO-211H cells serum-starved for 24 h and then treated with 50 nM progranulin for the indicated time.
E MSTO-211H cells were transfected with siRNA targeting progranulin or non-targeting control siRNA. At 8 h post-transfection cells were transferred
into serum-free medium for 40 h and then analyzed by immunoblot for total and phosphorylated levels of EphA2 (S897), AKT, ERK1/2 and
progranulin levels. F Levels of total and phosphorylated EphA2, AKT, ERK1/2 and progranulin were assessed by immunoblot in parental MSTO-211H,
MSTO-211H cells with progranulin knock-out by CRISPR/Cas9 (GRN KO) and GRN KO MSTO-211H cells with reconstituted progranulin expression
(left panel) or parental and progranulin overexpressing NCI-H2052 cells (right panel), serum-starved for 24 h. Progranulin levels were also analyzed
in conditioned media from cells starved for 48 h. G MSTO-211H and NCI-H2052 cells were serum-starved for 24 h, pre-incubated with either the
MEK1/2 inhibitor U0126 (10 µM) or the AKT inhibitor AKTi VIII (5 µM) for 2 h and then treated with the same concentrations of MEK1/2 and AKT
inhibitors alone or in combination with 50 nM progranulin for 15 min. Levels of total and phosphorylated EphA2, AKT and ERK1/2 were determined
by immunoblot
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Fig. 2 Progranulin and EphA2 differ in their ability to modulate mesothelioma cell motility and adhesion. A Migration of parental, GRN KO and
progranulin-re-expressing GRN KO MSTO-211H cells was assessed using transwells as described in Material and Methods. B Migration of parental,
GRN KO and EphA2 KO MSTO-211H cells as assessed by transwells migration. C Invasion of parental, GRN KO and EphA2 KO MSTO-211H cells was
assessed using matrigel-coated transwells. D The ability of parental, GRN KO and EphA2 KO MSTO-211H cells to adhere to plasma fibronectin,
collagen and poly-L-Lys was assessed as described in Material and Methods. E The migratory ability of parental and progranulin overexpressing
NCI-H2052 cells was assessed using transwells. F Transwell migration of parental and EphA2 KO NCI-H2052 cells, untreated or stimulated with
50 nM progranulin. G Invasion through matrigel-coated transwells of parental and EphA2 KO NCI-H2052 cells, untreated or stimulated with 50 nM
progranulin. For motility and adhesion assays, data are the average of three independent experiments ± SD. *** p < 0.001, ** p < 0.01, * p < 0.05. H
Parental, GRN KO and EphA2 KO MSTO-211H cells were subcutaneously implanted in Rag2-/- mice and tumor volumes measured at the indicated
time post tumor injection. N = 8, ± SD, * p < 0.05, ** p < 0.01

different action of progranulin and EphA2 in regulating
MSTO-211H cell motility, we then assessed cell adhesion
and evaluated the ability of parental, GRN and EphA2
KO MSTO-211H cells to adhere to different substrates,
including plasma fibronectin, collagen and poly-L-Lys.
As shown in Fig. 2D, GRN KO cells showed a significantly
reduced capacity to adhere to collagen when compared
to parental cells (Fig. 2D), whereas GRN KO and parental MSTO-211H cells showed similar adhesion to plasma
fibronectin and poly-L-Lys (Fig. 2D). By contrast, EphA2
KO MSTO-211H cells showed a significant increased
capacity to adhere to plasma fibronectin when compared
to both parental and GRN KO cells (Fig. 2D). All together
these results suggest that progranulin and EphA2 differ in their ability to modulate MSTO-211H adhesive
properties.
Next, we investigated progranulin and EphA2 action
in NCI-H2052 cell motility and adhesion. To this end,
we first stably transfected NCI-H2052 cells with a plasmid expressing human progranulin and then compared

the migratory ability of parental and progranulin-overexpressing cells. As shown in Fig. 2E, progranulin overexpression did not significantly affect the migration of
NCI-H2052 (Fig. 2E). We subsequently investigated
whether exogenous progranulin might modulate NCIH2052 cell migration. Surprisingly, progranulin-stimulated NCI-H2052 cells showed a marked reduction in
their migratory ability when compared to unstimulated
cells (Fig. 2F). Next, we tested cell migration of parental
and EphA2 KO NCI-H2052 cells. As shown in Fig. 2F,
EphA2 KO cells showed a reduced migratory capacity
in respect to parental cells and their migration was further reduced by recombinant progranulin (Fig. 2F). By
contrast, recombinant progranulin did not affect parental and EphA2 KO NCI-H2052 cells invasive abilities but
EphA2 KO cells showed increased basal (untreated cells)
invasiveness when compared to parental cells (Fig. 2G).
Based on these results, we then hypothesized that, in this
cell line, progranulin might preferentially modulate cell
adhesion. However, neither progranulin overexpression
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nor EphA2 deletion affected NCI-H2052 cell adhesion on
collagen, plasma fibronectin and poly-L-Lys or interfered
with cell–cell adhesion (Supplementary Fig. 2).
Finally, we compared the ability of parental, GRN or
EphA2 KO MSTO-211H cells to modulate in vivo tumor
formation. Cells were subcutaneously implanted in the
flank of Rag2 −/− mice and tumors were monitored until
they reached a volume of 1500 mm3. All cells generated
tumor xenografts, with parental and EphA2 KO MSTO211H cells showing similar in vivo tumor formation
(Fig. 2H). Notably, GRN KO cells generated tumors with
significantly higher tumor volume as compared to both
parental and EphA2 KO MSTO-211H cells (Fig. 2H).
These results suggest that EphA2 deletion is not critical
for in vivo tumor formation of MSTO-211H cells while
progranulin might play a more relevant role in modulating in vivo xenograft tumors.
Progranulin‑dependent activation of AKT and MAPK
pathways does not require EphA2 in mesothelioma

We previously demonstrated that EphA2 is the signaling receptor activated by progranulin in bladder cancer
[23, 24]. However, the phenotypes of GRN- and EphA2deleted cells considerably differed in their migratory, invasive and in vivo tumor formation ability, thereby suggesting
that EphA2 might not be the major functional progranulin receptor in mesothelioma. Thus, we investigated the
impact of EphA2 depletion on the activation of the AKT
and MAPK pathways in mesothelioma cells. As shown in
Fig. 3A, transient depletion of Epha2 by siRNA strategies
did not reduce AKT activation, which was instead clearly
affected by transient depletion of progranulin. In addition,
the combined depletion of EphA2 and progranulin attenuated the reduction of AKT activation caused by progranulin depletion alone (Fig. 3A). These data demonstrate that
progranulin-dependent activation of AKT does not require
EphA2. In agreement, MSTO-211H cells with a genetic
ablation of EphA2 showed similar basal pAKT levels when
compared to parental MSTO-211H cells (Fig. 3B). In addition, progranulin transient depletion by siRNA led to a
reduction in pAKT levels in both parental and EphA2 KO
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MSTO-211H cells (Fig. 3B). We then analyzed the effect
of progranulin depletion on AKT activation in EphA2 KO
MSTO-211H cells with reconstituted expression of wild
type or EphA2 mutants. We expressed wild type EphA2,
a kinase-inactive EphA2 mutant (EphA2 K646M) and an
EphA2 mutant where the three serine residues at positions
897, 899 and 901, which we identified as phosphorylated
upon progranulin stimulation [24], were substituted with
alanine residues (EphA2 S897A/S899A/S901A) (Supplementary Fig. 1). Progranulin depletion inhibited AKT activation in all cell lines, further confirming that endogenous
progranulin sustains AKT activation in EphA2-independent manner in MSTO-211H cells (Fig. 3B). We then tested
whether exogenous progranulin activates AKT and ERK1/2
in MSTO-211H cells lacking EphA2, by comparing EphA2
KO cells to EphA2 KO MSTO-211H cells re-expressing
wild-type EphA2. Notably, progranulin stimulation triggered AKT and, to a lesser extent, ERK activation independently of the presence of EphA2 (Fig. 3C), further
confirming that EphA2 is not required for progranulindependent downstream signaling in MSTO-211H. We confirmed these results in parental and EphA2 KO NCI-H2052
cells further demonstrating that the activation of AKT and
MAPK does not require EphA2 (Fig. 3D and and Supplementary Fig. 4D). In summary, these data suggest that
progranulin action in mesothelioma cells does not either
rely on EphA2 activation or that mesothelioma cells might
compensate for the lack of EphA2 by promoting progranulin-dependent AKT and ERK1/2 activation in an EphA2independent manner.
Role of Focal adhesion kinase (FAK) in regulating
progranulin‑dependent activation of AKT and MAPK
in mesothelioma

Since it has been previously demonstrated that progranulin modulated focal adhesion kinase (FAK) [18] and
FAK plays an important role in modulating growth factors-dependent activation of the AKT and MAPK pathways [40, 41], we investigated the potential role of FAK
in mediating progranulin-evoked activation of the AKT
and MAPK pathways. Thus, we treated parental, EphA2

(See figure on next page.)
Fig. 3 Progranulin activates AKT and ERK1/2 in an EphA2-independent manner in mesothelioma cells. A MSTO-211H cells were transfected
with siRNA targeting either GRN (progranulin), EphA2, the combination of the two or non-targeting control (siCTR). At 8 h post-transfection cells
were transferred to serum-free media and incubated for additional 40 h. Cells were then treated with 50 nM progranulin for 60 min. Levels of
progranulin, total and phosphorylated EphA2 (S897), AKT and ERK1/2 were analyzed by immunoblot. B GRN was depleted using siRNAs targeting
progranulin as described in (A) in parental MSTO-211H (P), EphA2 KO MSTO-211H and EphA2 KO cells re-expressing wild type EphA2 or the EphA2
mutants EphA2 K646M and EphA2 S897A/S899A/S901A. Levels of progranulin, total and phosphorylated EphA2 (S897), AKT and ERK1/2 were
determined by immunoblot. C Total and phosphorylated EphA2 (S897), AKT and ERK1/2 as assessed by immunoblot in EphA2 KO MSTO-211H
cells stably transfected with an empty vector or re-expressing wild-type EphA2, serum-starved for 24 h and exposed to 50 nM progranulin for the
indicated time. D Parental (P) NCI-H2052 cells, two different EphA2 KO NCI-H2052 clones and a non-targeting control (NTC) NCI-H2052 clone were
serum-starved for 24 h and then stimulated with 50 nM progranulin for 15 min. Levels of total and phosphorylated EphA2, AKT and ERK1/2 were
analyzed by immunoblot
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Fig. 3 (See legend on previous page.)

KO MSTO-211H (Fig. 4A) and NCI-H2052 (Fig. 4B)
cells with the FAK inhibitor PF-573228 alone or in combination with progranulin. In MSTO-211H cells FAK

inhibition led to a significant inhibition of ERK activation, both in basal conditions and upon progranulinstimulation, and to a partial inhibition of AKT activation
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Fig. 4 FAK mediates progranulin-dependent activation of AKT and ERK1/2 in mesothelioma cells. A, B Parental and EphA2 KO MSTO-211H (A) and
NCI-H2052 (B) cells were serum-starved for 24 h, pre-incubated with the FAK inhibitor PF-573228 (5 µM) for 1 h and then treated with the same
concentration of PF-573228 alone or in combination with 50 nM progranulin for 15 min. Levels of total and phosphorylated EphA2 (S897), AKT,
ERK1/2 and FAK (Y397) were assessed by immunoblot. C NCI-H2052 cells were transfected with siRNA targeting FAK (PTK2) or non-targeting control
(siCTR) siRNA. At 48 h post-transfection cells were transferred onto serum-free medium and 24 h later exposed to 50 nM progranulin for 15 min.
Levels of total and phosphorylated EphA2 (S897), AKT, ERK1/2 and of FAK as assessed by immunoblot

in both parental and EphA2 KO cells (Fig. 4A), suggesting that FAK might have a critical role in controlling ERK
activation but only a minor role in modulating AKT signaling in this cell model. In NCI-H2052 cells, both AKT
and MAPK pathways were inhibited upon FAK inhibition (Fig. 4B), suggesting a strong dependency of these
pathways on FAK activity in this cell model. In agreement, transient knock-down of FAK in NCI-H2052 cells
inhibited progranulin-dependent activation of AKT and
ERK1/2 (Fig. 4C and Supplementary Fig. 4E). Notably, in
both cell lines, FAK inhibition led to a reduction in the
levels of phosphorylated EphA2 at S897 (Fig. 4 A-C).
Since we demonstrated that EphA2 phosphorylation at
S897 mainly relies on ERK1/2 (Fig. 1G), these data suggest that FAK, by controlling ERK1/2 activation, might
indirectly sustain EphA2 phosphorylation at S897 in
mesothelioma cells.
Progranulin promotes the activation of multiple RTKs
in mesothelioma cells

Contrary to our previous data in bladder cancer [23, 24],
our results suggest that EphA2 is not the main functional
progranulin signaling receptor in mesothelioma. In addition, recent data have suggested that progranulin might
have the ability to activate multiple RTK signaling pathways in cell context-dependent manner [42]. Thus, to
identify receptor tyrosine kinases (RTKs) activated by
progranulin in mesothelioma cells, we used an unbiased

approach by testing antibody arrays that simultaneously
assess tyrosine-phosphorylation levels of 49 different
human RTKs and exposed these arrays to lysates derived
from unstimulated (SFM) or progranulin-stimulated
MSTO-211H or NCI-H2052 cells. In MSTO-211H cells,
progranulin promoted a significant increase in total
tyrosine phosphorylation of EGFR, EphA7 and RYK
(Fig. 5, left panels) while in NCI-H2052 cells, progranulin
induced a significant increase of RYK tyrosine phosphorylation and a minor increase in EGFR phosphorylation
(Fig. 5, right panels). Notably, in these experimental conditions we did not detect tyrosine-phosphorylation of
EphA2. Based on these results, we initially investigated
the potential role of EGFR in mediating progranulindependent activation of AKT and ERK1/2. In MSTO211H cells, both EphA2 KO cells and EphA2 KO cells
re-expressing wild type EphA2, pharmacological inhibition of EGFR by the specific, clinical grade, EGFR inhibitor gefitinib reduced pAKT and pERK1/2 levels and
prevented progranulin-evoked AKT and ERK1/2 activation (Fig. 6A, left panel), thereby confirming the role of
EGFR in mediating progranulin-dependent signaling in
MSTO-211H cells. Interestingly, EGFR inhibition led
to decreased EphA2 S897 phosphorylation (Fig. 6A, left
panel), suggesting that EGFR is at least in part involved
in controlling EphA2 serine-phosphorylation in these
cells. We performed similar experiments in NCI-H2052
cells where EGFR inhibition was associated with a
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Fig. 5 Multiple RTKs are activated by progranulin in mesothelioma cells. A Phospo-RTK arrays were treated with lysates from MSTO-211H or
NCI-H2052 cells in SFM or treated with 10 nM progranulin for 15 min. Data are mean ± SD, ** p < 0.01, * p < 0.05

reduction in the basal levels of pAKT but not pERK1/2
and inhibited progranulin-dependent activation of AKT
but not of ERK1/2 (Fig. 6A, right panel), suggesting a
more restricted role for EGFR in mediating progranulindependent activation of AKT in this cell model. Notably,
as in MSTO-211H, EGFR inhibition attenuated the phosphorylation of EphA2 on S897 in NCI-H2052 cells as well
(Fig. 6A, right panel), suggesting a modulation of EphA2
activity by EGFR in mesothelioma cells. Based on these
results, we investigated whether endogenous progranulin
might affect EGFR activation in mesothelioma cells. As
shown in Fig. 6B, MSTO-211H cells with transient depletion of progranulin by siRNA strategies showed reduced
EGFR phosphorylation at Y1068 when compared to
siControl-transfected cells (Fig. 6B, left upper panel, and
Supplementary Fig. 4F), indicative of a reduced activation of EGFR. In agreement, progranulin overexpressing NCI-H2052 cells showed slightly increased levels of
pEGFR Y1068 when compared to parental NCI-H2052
cells (Fig. 6B, right upper panel, and Supplementary
Fig. 4F), suggesting that EGFR activation is dependent on progranulin expression levels. All together these
results suggest that progranulin modulates EGFR activation in mesothelioma cells. To confirm these data, we
compared the levels of pEGFR Y1068 in parental and

GRN KO MSTO-211H cells. Notably, we observed higher
pEGFR Y1068 phosphorylation levels in GRN KO than
in parental MSTO-211H cells (Fig. 6B, lower panel, and
Supplementary Fig. 4F). These data indicate a complex
modulation of EGFR activity by endogenous progranulin
and suggest that progranulin genetic deletion might trigger homeostatic compensatory mechanisms leading to
enhanced EGFR activation. Considering that EGFR inhibition reduced pEphA2 S897 and pAKT levels (Fig. 6A),
we hypothesized that the enhanced pEGFR Y1068 levels in GRN KO MSTO-211H cells might determine the
increase in pEphA2 S897 and pAKT levels observed in
this cell line as compared to parental MSTO-211H cells
(Fig. 1F). Indeed, the inhibition of EGFR strongly reduced
both pEphA2 S897 and pAKT levels (Fig. 6C), suggesting
that the increased activity of EGFR in GRN KO MSTO211H cells is, at least in part, responsible for the increased
levels of pEphA2 S897 and pAKT observed in this cell
line. Next, we investigated the potential role of EphA7 in
regulating progranulin downstream signaling in MSTO211H cells. Significantly, transient depletion of EphA7 by
siRNA approaches increased basal levels of pAKT and
pERK1/2 (Fig. 6D), suggesting that EphA7 might have an
inhibitory action on AKT and MAPK, ruling out a possible role for EphA7 in mediating progranulin-induced

(See figure on next page.)
Fig. 6 EGFR and RYK sustain progranulin signaling in mesothelioma cells. A Total and phosphorylated EphA2 (S897), AKT and ERK1/2 in EphA2
KO MSTO-211H cells stably transduced with an empty vector or re-expressing wild type EphA2 (left panel) and NCI-H2052 cells (right panel)
pre-incubated with the EGFR inhibitor gefitinib (10 µM) for 1 h and then exposed to the same concentration of gefitinib alone or in combination
with 50 nM progranulin for 15 min. B Total and phosphorylated EGFR (Y1068) in MSTO-211H cells transfected with GRN-specific or non-targeting
control (siCTR) siRNA (upper left panel), parental and PGRN overexpressing NCI-H2052 cells (upper right panel) and parental, GRN KO or
PGRN-reconstituted GRN KO MSTO-211H cells (lower panel) after serum-starvation for 24 h. C Levels of total and phosphorylated EGFR (Y1068),
EphA2 (S897) and AKT in parental or GRN KO MSTO-211H cells serum-starved for 24 h and treated with gefitinib (10 µM) for 1 h 30 min. D Levels
of EphA7, total and phosphorylated EphA2 (S897), AKT and ERK1/2 in MSTO-211H cells transfected with EphA7-specific or control (siCTR) siRNA,
transferred onto serum-free 24 h post transfection, incubated for additional 24 h and then treated with 50 nM progranulin for 15 min. E MSTO-211H
and NCI-H2052 cells were transfected with siRNA specific for RYK or non-targeting control (siCTR) siRNAs. At 48 h post-transfection cells were
transferred onto serum-free medium and incubated for 24 h. Cells were then treated with 50 nM PGRN for 15 min. Total and phosphorylated EphA2
(S897), AKT and ERK1/2 were analyzed by immunoblot. F-G Total and phosphorylated AKT and ERK1/2 in NCI-H2052 transfected with siRYK or
control siRNA (siCTR) (F) or stably expressing two different RYK-specific or a non-targeting control (shCTR) shRNA treated with 10 µM gefitinib for 1 h
and then exposed to the same concentration of gefitinib alone or in combination with 50 nM progranulin for 15 min
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activation of these two signaling pathways. Finally, we
investigated the potential role played by RYK in both
MSTO-211H and NCI-H2052 by transiently knockingdown RYK using siRNA approaches. Given the very limited availability of reliable antibodies for RYK, we verified
the efficiency of RYK knock-down by measuring mRNA
levels. As shown in Supplementary Fig. 3A, siRYK-transfected cells showed a significant reduction in RYK mRNA
levels (about 80%). In MSTO-211H cells, RYK depletion
reduced pAKT basal levels and inhibited progranulininduced activation of both AKT and ERK1/2, whereas in
NCI-H2052 RYK knock-down had only a minor effect on
AKT activation without affecting pERK1/2 levels (Fig. 6E
and Supplementary Fig. 4G). Thus, we hypothesized that,
in NCI-H2052, EGFR might compensate for RYK loss
and sustain AKT and ERK activation in RYK-depleted
NCI-H2052 cells. To test this hipothesis, we exposed
siRYK- and siCTR-transfected NCI-H2052 cells to the
EGFR inhibitor gefitinib alone or in combination with
progranulin. As shown in Fig. 6F, the combined inhibition of EGFR and RYK was more effective than the inhibition of EGFR alone in reducing the activation of AKT
(Fig. 6F, RYK mRNA levels reported in Supplementary
Fig. 3B). To confirm these results with a complementary
approach, we performed similar experiments in NCIH2052 cells stably transduced with two different RYKspecific shRNAs (Fig. 6G and Supplementary Fig. 4H,
RYK mRNA levels reported in Supplementary Fig. 3C) or
non-silencing shRNA control. As shown in Fig. 6G, the
inhibition of EGFR led to a significantly stronger reduction of pAKT levels in shRYK- than in shCTR-transduced
cells, both in basal conditions and upon progranulin
stimulation. Taken together, these results suggest that
progranulin might sustain the activation of multiple
RTKs in mesothelioma cells and signaling triggered by
progranulin to AKT and MAPK activation might rely on
EGFR and RYK in mesothelioma cells.
Progranulin modulates FAK activity and focal adhesion
turnover

Because progranulin affected mesothelioma cell motility and adhesion (Fig. 2) and FAK plays a role in mediating progranulin-activated downstream signaling
(Fig. 4), we then asked whether progranulin modulation
of mesothelioma cell motility might depend on FAK
activity. To this end, we first investigated the effect of
endogenous progranulin on FAK phosphorylation. We
transiently depleted progranulin by siRNA in MSTO211H cells and observed an increase in pFAK Y397 levels in progranulin-depleted cells as compared to siRNA
control-treated cells (Fig. 7A). Notably, progranulin
depletion was associated with increased in pFAK Y397
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levels in EphA2 KO MSTO-211H cells and in MSTO211H cells expressing either wild type, K646M or
EphA2 S897A/S899A/S901A EphA2 (Fig. 7A), indicating that the effect of progranulin on pFAK Y397 does
not require an active EphA2. To confirm this data,
we analyzed by immunoblot pFAK Y397 in GRN KO
MSTO-211H cells and in GRN KO MSTO-211H cells
with reconstituted progranulin expression. As shown in
Fig. 7B, GRN KO cells showed higher pFAK Y397 levels when compared to MSTO-211H parental cells and
the reconstitution of progranulin expression partially
reduced pFAK Y397 levels observed in GRN KO cells
(Fig. 7B, left panel, and Supplementary Fig. 4I), confirming the role of progranulin in modulating pFAK
Y397 levels. We then analyzed pFAK Y397 levels in
NCI-H2052 and observed a slight reduction in FAK
phosphorylation at Y397 in cells over-expressing progranulin when compared to parental cells (Fig. 7B, right
panel, and Supplementary Fig. 4I), further demonstrating that progranulin modulates FAK phosphorylation
in these cells.
Since we have demonstrated that progranulin might
activate EGFR and RYK in mesothelioma (Figs. 5 and 6)
and considering that both EGFR and RYK might directly
or indirectly modulate FAK activity [43–46], we asked
whether progranulin-dependent regulation of FAK activity was mediated by EGFR and/or RYK. We therefore
depleted RYK by siRNA strategies in MSTO-211H and
NCI-H2052 cells (RYK mRNA levels reported in Supplementary Fig. 3D) and exposed both siControl- and
siRYK-transfected cells to the EGFR inhibitor gefitinib,
progranulin or the combination and analyzed FAK levels. As shown in Fig. 7C, neither cell exposure to the
EGFR inhibitor nor cell treatment with progranulin significantly affected pFAK Y397 levels, whereas RYK gene
knock down led to a reduction of pFAK Y397 levels
and to a lesser extent in total levels of FAK in both cell
lines (Fig. 7C), pointing out an important role of RYK in
modulating FAK activity in mesothelioma. Significantly,
similar results were obtained in EphA2 KO MSTO211H cells (Fig. 7D, RYK mRNA levels in Supplementary Fig. 3E), suggesting that RYK action on FAK activity
does not require EphA2. We then investigated whether
the increase in pFAK Y397 levels we observed in MSTO211H cells upon progranulin depletion was RYK-dependent. Thus, we transiently depleted both progranulin and
RYK and observed that RYK knock-down abolished
the increase in pFAK Y397 levels associated with progranulin depletion (Fig. 7E and Supplementary Fig. 4J,
RYK mRNA levels in Supplementary Fig. 3F). Accordingly, RYK depletion reduced the levels of pFAK Y397 in
GRN KO MSTO-211H cells (Fig. 7F and Supplementary
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Fig. 7 Progranulin modulates pFAK Y397 levels in a RYK-dependent manner and modulates focal adhesion turn over. A Parental (P), EphA2 KO and
EphA2 KO MSTO-211H cells stably transfected with an empty vector, re-expressing wild type EphA2, or EphA2 mutants were transfected with siRNAs
targeting progranulin (siGRN) or non-targeting (siCTR) control. At 8 h post-transfection cells were serum-starved and total and phosphorylated FAK
(Y397) were analyzed by immunoblot 48 h post-transfection. B Phosphorylated FAK (Y397) levels in parental, GRN KO, GRN KO MSTO-211H cells
with reconstituted progranulin expression (left panel) or parental and PGRN overexpressing NCI-H2052 cells (right panel) serum-starved for 24 h.
C Phosphorylated FAK (Y397) in siRYK- or siControl-transfected (siCTR) MSTO-211H and NCI-H2052 cells serum-starved for 24 h, pre-incubated
with gefitinib (10 µM) for 1 h and then treated with gefitinib alone or in combination with 50 nM progranulin for 15 min. D Levels of total and
phosphorylated FAK (Y397) in EphA2 KO MSTO-211H cells transfected with siRNA targeting RYK or control (siCTR) siRNA, serum-starved for 24 h and
stimulated with 50 nM progranulin for 15 min. E Levels of total and phosphorylated FAK (Y397) in MSTO-211H cells transfected with either siRNAs
targeting progranulin, RYK, their combination or non-targeting controls (siCTR) and serum-starved for 40 h. F Levels of total and phosphorylated
FAK (Y397) in parental and GRN KO MSTO-211H cells transfected with siRYK or control (siCTR) siRNA and serum-starved for 24 h. G-I Parental and
GRN KO MSTO-211H cells (G), parental MSTO-211H cells 24 h post transfection with siRNA targeting progranulin (siGRN) or control ( siCTR) siRNA
(H), and GRN KO MSTO-211H cells 48 h post transfection with RYK-specific siRNA or control (siCTR) siRNA (I) were serum-starved for 24 h and then
treated with 10 µM nocodazole (NCZ) for 4 h. Nocodazole was then washed-out and the levels of phosphorylated FAK (Y397) were analyzed by
immunoblot in cell lysates at the indicated times after nocodazole washout

Fig. 4 K, RYK mRNA levels in Supplementary Fig. 3G).
Taken together these data suggest that progranulin modulates FAK phosphorylation at Y397 in RYK-dependent
fashion.
Since the modulation of FAK phosphorylation at Y397
is associated with focal adhesion (FA) turnover [47], we
investigated whether progranulin might affect the kinetics of FAs assembly/disassembly, which is a critical step
in the regulation of cell motility [47]. To this end we used
a biochemical assay that allows the detailed modulation
of FAs turn-over by disrupting the microtubules, which
are implicated in FA turnover and cell migration [48–50].
Briefly, cells are first treated with the microtubules-destabilizing drug nocodazole to induce the formation of FAs.
Nocodazole is then washed out and the kinetics of FA
disassembly and reassembly is evaluated by monitoring
the levels of pFAK Y397, as in fact FAK is phosphorylated

at Y397 during FA assembly and dephosphorylated upon
FA disassembly, which is the essential step for initiating
migration [50, 51]. Thus, we exposed parental and GRN
KO MSTO-211H cells to nocodazole, we then washed it
out and analyzed the levels of pFAK Y397 over time. The
data shown in Fig. 7G confirmed that GRN KO cells have
higher basal levels of pFAK Y397 than parental cells. As
expected, pFAK Y397 levels increased in both cell lines
upon cell treatment with nocodazole, which freezes FAs
in the assembled state. After nocodazole release the
levels of pFAK Y397 decreased in both cell lines but to
a significantly reduced extent in GRN KO cells, where
pFAK Y397 levels rapidly increased again, indicating a
significantly impaired FA disassembly in GRN KO cell
as compared to parental MSTO-211H cells (Fig. 7G and
Supplementary Fig. 4L). Similar results were obtained
in parental MSTO-211H cells with transient depletion

Ventura et al. J Exp Clin Cancer Res

(2022) 41:333

of progranulin by siRNA (Fig. 7H and Supplementary
Fig. 4M). To investigate whether progranulin-dependent
modulation of FA turnover might involve RYK, we performed a similar experiment in GRN KO MSTO-211H
cells transiently transfected with siRNA targeting RYK
or controls. As shown in Fig. 7I, RYK transient depletion
in GRN KO cells showed a persistent reduction in the
phosphorylation of FAK Y397 after nocodazole release as
compared to siControl-transfected cells (Fig. 7I and Supplementary Fig. 4N, RYK mRNA levels in Supplementary
Fig. 3H), suggesting that progranulin-evoked modulation
of FA disassembly is regulated by RYK.
We then used a complementary approach and detected
FAs by immunofluorescence using pFAK Y397 and vinculin as FAs markers. At 30 min after nocodazole washout FAs could not be detected in parental MSTO-211H
cells whereas they could still be detected in GRN KO
MSTO-211H cells (Fig. 8A, arrows), suggesting that FAs
completely disassembled in MSTO-211H parental cells
whereas they only partially disassembled in cells lacking progranulin. At 60 min after nocodazole washout
FAs could not be detected in both cell lines (Fig. 8A).
Collectively these data suggest that cells lacking progranulin have a delayed FAs disassembly. At 90 min
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from nocodazole release FAs started reforming and
they could be detected again in both parental and GRN
KO MSTO-211H KO cells 2 h post nocodazole release
(Fig. 8A, arrows). We then monitored the formation of
F-actin-containing cell protrusions in the same experimental conditions. As shown in Fig. 8B, F-actin-containing cell protrusions were already visible at 30 min
after nocodazole wash out in parental cells, whereas in
GRN KO MSTO-211H cells they were detectable at the
later time point of 60 min (Fig. 8B, arrows). All together
these data suggest that cells lacking progranulin have different kinetics of FAs turnover and cytoskeleton rearrangements, suggesting that progranulin modulates
mesothelioma cell motility by affecting FAs disassembly
and the formation of cellular protrusions.

Discussion
Mesothelioma is a rare aggressive malignancy with limited therapeutic options and the response to currently
available therapies is highly dependent on tumor histologic subtype [7]. Progranulin is a pleiotropic growth
factor playing a critical role in cell proliferation, angiogenesis, and development [34, 52]. Progranulin is often
dysregulated in cancer, where it affects both tumor

Fig. 8 Progranulin modulates focal adhesion turnover and the formation of F-actin-containing cell protrusions. A-B Serum-starved parental and
GRN KO MSTO-211H cells were treated with 10 µM nocodazole (NCZ) for 4 h. Nocodazole was then washed out to allow microtubules regrowth
and focal adhesion assembly. Cells were fixed at the indicated time points after nocodazole release and stained for pFAK Y397 and vinculin (A) or
vinculin and F-actin (B) by immunofluorescence. Bars = 20 µm. Arrows indicate focal adhesion (A) or F-actin containing cell protrusions (B)
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initiation and progression [53]. Very little is currently
known about the role of progranulin in mesothelioma but
data suggest a role of progranulin in regulating angiogenesis in a VEGF-independent manner [30]. Here, we demonstrate that: 1) progranulin is expressed at high levels in
mesothelioma cell lines representative of various mesothelioma histopathological subtypes as compared to nontransformed mesothelial cells; 2) progranulin sustains
the activation of the AKT and MAPK signaling pathways
in mesothelioma cells, with progranulin signaling being
mediated by EGFR, RYK and FAK; 3) progranulin modulates mesothelioma cell migration, invasion, adhesion
and in vivo tumor growth; 4) progranulin regulates focal
adhesion turnover by affecting FAK activation in a RYKdependent manner. Thus, our results suggest a complex
and critical role for progranulin in modulating mesothelioma cell transformation.
Although progranulin oncogenic role has been demonstrated in several tumor types, how progranulin exerts its
activity is not fully defined. Indeed, progranulin mechanism of action might rely on its ability to interact with
multiple proteins, including component of the extracellular matrix, cell membrane receptors and non-receptor
proteins, lysosomal enzymes and trafficking proteins
[52]. Our group has recently demonstrated that in bladder cancer progranulin oncogenic activity relies on
EphA2, which is the progranulin functional receptor in
this tumor model [23, 54]. In bladder cancer, EphA2 activation by progranulin mediates progranulin-dependent
activation of AKT and MAPK pathways, thereby sustaining EphA2 phosphorylation at S897 [24]. Here, we
found that pEphA2 S897 levels were higher in mesothelioma cells than normal mesothelial cells and that
EphA2 phosphorylation at S897 was sustained by progranulin stimulation in an ERK1/2-dependent manner.
However, EphA2 is not the main receptor of progranulin in this system as in fact EphA2 deletion by CRISPR/
Cas9 approaches did not prevent progranulin-dependent
activation of AKT and MAPK pathways. More importantly, the phenotypes of GRN- and EphA2-deleted cells
were very different in terms of cell migration, invasion,
adhesion and in vivo tumor formation. In addition, the
biological function of progranulin and EphA2 differed in
the two cell line models MSTO-211H and NCI-H2052.
All together, these results suggest that EphA2 is not the
main mediator of progranulin action in mesothelioma
cells and that the role of progranulin and EphA2 in mesothelioma is context dependent and might depend on
the specific mesothelioma tumor subtype. In addition,
EphA2 is phosphorylated at S897 in mesothelioma cells
but the relevance of this event is not clear at the moment.
In order to explain the different effects of progranulin on
cell motility of MSTO-211H and NCI-H2052 cells, we
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should consider that progranulin can be processed by
different proteases into smaller granulins, which often
have opposing biological functions [55, 56]. Thus, we can
hypothesize that, in NCI-H2052, progranulin could be
processed into granulins with an inhibitory effect on cell
migration. Further experiments are required to fully elucidate these differences, which might also depend on the
particular MM subtype from which cells were derived.
In agreement with the results obtained in EphA2 KO
cells pointing out that EphA2 is not the principal progranulin receptor in mesothelioma, in phospho-RTK
arrays-based experiments we did not detect any increase
in EphA2 tyrosine phosphorylation in mesothelioma cells
stimulated with progranulin, indicating that EphA2 is not
directly activated by progranulin in this model. By contrast, the phospho-RTK array data suggested that EGFR,
RYK and EphA7 are activated upon progranulin stimulation of mesothelioma cells. Thus, these results suggest
that progranulin has an important role in sustaining the
activity of RTKs important for the establishment and
maintenance of mesothelioma malignant phenotype.
As mentioned above, EphA2 is the key mediator of progranulin signaling in bladder cancer where progranulin
did also modestly activate EGFR, EphA4 and EphB2 [23].
In mammary epithelial cells multiple RTKs are activated
by progranulin, including EGFR, ERBB2 and members
of the Eph family [42]. In the neuron-like cell line NSC34, progranulin also promoted the activation of RET
[42]. Thus, our results further support the notion that
progranulin might activate multiple RTKs and that progranulin downstream oncogenic signaling might be cell
context-dependent.
The modulation of EGFR activity by progranulin was of
particular interest. EGFR inhibition affected progranulindependent activation of AKT and MAPK and transient
progranulin depletion led to a reduction in the levels of
pEGFR Y1068 in MSTO-211H cells. However, genetic
ablation of progranulin in MSTO-211H cells enhanced
both total EGFR and pEGFR Y1068 levels in GRN KO
cells. The increase in EGFR levels and activity might
represent a homeostatic compensatory mechanism for
progranulin loss in mesothelioma, which is reminiscent
of the increase in expression of several neurotrophic
receptors, including RTKs, molecules of the semaphorinsignaling pathway, Notch-related receptors and receptors
belonging to the WNT signaling pathways, observed in
progranulin-depleted neuronal cells [42]. Notably, the
increase of EGFR activity detectable in GRN KO cells
might explain the enhanced pAKT and pEphA2 S897
levels observed in this cell line as compared to parental cells. Indeed, we showed that in MSTO-211H cells
EGFR modulates both AKT and EphA2 S897 phosphorylation and that the inhibition of EGFR in GRN KO
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cells strongly reduced the levels of both EphA2 S897 and
pAKT. Importantly, the increase in both EGFR and AKT
activity in GRN KO cells might explain the paradoxical
behavior shown by these cells in vivo, as in fact GRN KO
cells formed larger tumors than parental cells, in spite
of reduced motility and invasive ability. This result was
somewhat unexpected but not totally surprising, as these
data are similar to previously published work on ERK5
oncogene deletion, which accelerated in vivo tumor
growth while inhibiting tumor invasion of breast cancer
cells [57].
These results should be taken into account when
designing potential therapeutic strategies targeting progranulin, as in fact they suggest the need for combinatorial treatments targeting not only progranulin but also
the compensatory molecular pathways activated upon
progranulin deletion. However, it is important to keep
in mind that pharmacological targeting of progranulin
might have an effect different from progranulin genetic
deletion.
Interestingly, our results provide the first evidence
that progranulin might modulate RYK activity. RYK is
considered a receptor or coreceptor for the WNT signaling pathway [58, 59] and can mediate both canonical
and non-canonical WNT signaling [60], even though the
molecular mechanisms of action are not clearly defined.
Indeed, RYK does not appear to have intrinsic kinase
activity [61] and it might actually work by functionally interacting with intracellular proteins such as c-SRC
or membrane receptors including DZ and Eph receptors [62, 63]. RYK signaling in cancer is highly context
dependent. In gastric cancer and glioma, RYK promotes
cell migration and invasion [64–66] whereas in prostate
cancer Wnt5a-RYK have pro-apoptotic and pro-proliferative action [67]. In lung cancer, RYK promotes resistance
acquired upon EGFR inhibition [68]. In mesothelioma,
the WNT pathway controls cell proliferation, apoptosis
and cisplatin-resistance [69–71] and RYK phosphorylation was observed in 7 out of 12 diffuse malignant peritoneal mesothelioma frozen samples [72]. However, the
role of RYK in mesothelioma cells remains unexplored.
In addition, there are no reports suggesting a role of progranulin in directly modulating the WNT pathway in
cancer, even though recent data have demonstrated that
progranulin depletion might increase the expression of
some WNT pathways receptors [42]. In addition, GRN
haploinsufficiency detectable in patients with frontotemporal lobar degeneration is associated with Wnt5a
signaling in neuronal cells but no connection with RYK
has been established [73, 74]. Thus, whether progranulin might directly interact with RYK, thereby competing
with WNT proteins for RYK binding, is currently not
established. Notably, it has been reported a role of RYK
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in modulating PI3K/AKT pathway [75]. Accordingly, our
results demonstrate RYK action in modulating AKT activation in mesothelioma, as in fact RYK depletion inhibited basal and progranulin-dependent AKT activity.
Interestingly, both EGFR and RYK inhibition led to a
reduction of pEphA2 S897 levels, suggesting that EphA2
S897 phosphorylation observed upon progranulin
stimulation might not be direct but secondary to EGFR
and RYK activation. The crosstalk between EphA2 and
EGFR is well documented and this functional interaction is quite complex and context-dependent being both
protumorigenic [76] and anti-migratory, by inhibiting
EGF-modulated AKT activation [77]. Similarly, there
are reports suggesting that Eph receptors, including
EphA2, might cross-talk with RYK and promote RYK
phosphorylation [63]. Previous data have demonstrated
that several RTKs are coactivated in mesothelioma cells
and sustain the activity of the AKT and MAPK pathways, suggesting that the combined inhibition of multiple RTKs would be the best strategy to counteract their
pro-tumorigenic action [72, 78]. Our results highlight the
complexity of progranulin signaling in mesothelioma and
suggest that progranulin might be a growth factor able to
sustain the activation of multiple RTKs, thereby modulating their crosstalk and downstream activation of AKT
and MAPK signaling. The picture is even more complex
if we consider that the results of the phospho-RTK arrays
suggested that EphA7 might be also tyrosine-phosphorylated upon progranulin stimulation. The role of EphA7 in
cancer is very controversial and context-dependent, with
reports suggesting both pro-malignant and anti-tumorigenic function [63]. Our data suggest that EphA7 might
have a tumor suppressive role in mesothelioma, since
EphA7 depletion did not prevent progranulin-dependent
AKT and MAPK activation but led instead to an increase
in basal activation of these two signaling pathways.
FAK is a key regulator of mesothelioma cell proliferation, survival, migration, invasion, adhesion and maintenance of cancer stem cells (CSC) and is becoming a very
attractive target for cancer therapy [79–81]. Mesothelioma cells lacking the expression of the tumor suppressor neurofibromatosis type 2 (NF2) gene, merlin, show
strong dependency on FAK signaling [82, 83]. NF2 mutations are among the most common genetic alterations
in mesothelioma, with NF2 biallelic loss being present
in about 40% to 50% of tumors [83]. Merlin is expressed
at the cell–cell boundary where it controls the maturation of adherens junctions. Cells lacking merlin have
weaker cell–cell adhesion, rely on FAK-evoked survival
signals coming from the extracellular matrix [83], show
altered RTKs trafficking [84] and present enhanced RasMEK1/2-ERK1/2 signaling [82]. Based on these published data, we can therefore speculate that the presence

Ventura et al. J Exp Clin Cancer Res

(2022) 41:333

or absence of merlin in mesothelioma cells might determine different EGFR/RYK endocytosis/sorting, which
could modulate the intensity of progranulin-dependent
downstream signaling.
This study highlights a complex modulation of FAK
activity by progranulin. Indeed, FAK inhibition had a
strong inhibitory effect on ERK1/2 activation and abolished progranulin-dependent activation of ERK1/2
independently of EphA2, in both MSTO-211H and NCIH2052 cells, demonstrating the role for FAK in mediating
progranulin-dependent activation of MAPK in mesothelioma. In addition, we showed that FAK modulated EphA2
phosphorylation at S897. This aspect might be relevant
for NCI-H2052 cells, where activated EphA2 might partially control cell migration. In addition, it might have
a role in MSTO-211H cell adhesion to fibronectin considering that EphA2 KO MSTO-211H cells showed an
increased adhesion to fibronectin when compared to
parental cells. Notably, an interplay between EphA2, FAK
and fibronectin has been recently reported [85]. Finally,
in NCI-H2052 cells (merlin-negative), FAK inhibition
had a strong inhibitory effect on AKT activation, both
basal and progranulin-dependent, whereas the effect was
only minor in MSTO-211H cells (merlin-positive). These
data are in agreement with the results reported by Shapiro et al. [83], who demonstrated that the modulation of
AKT by FAK is affected by merlin expression in mesothelioma cells. Considering the relevance of FAK and AKT
in promoting cell migration and adhesion, we can therefore speculate that the difference in progranulin-evoked
migratory and adhesive response between MSTO-211H
and NCI-H2052 cells could be dependent on the presence or absence of merlin, which might be critical for
FAK activity. We additionally demonstrated that progranulin depletion in MSTO-211H cells led to significant
increase in FAK Y397 phosphorylation. Interestingly, this
effect was reverted by RYK depletion, suggesting that
this process is RYK-dependent, thereby pointing out a
complex interplay between progranulin, FAK and RYK.
Of note, RYK depletion led to reduced levels of pFAK
Y397 in both MSTO-211H and NCI-H2052, suggesting a novel role for RYK in modulating FAK activity. A
functional cross-talk between WNT and FAK pathways
has been previously reported in several cancer models
[45, 46], but there are no data supporting a role of RYK in
this process. Given the key role of FAK in mesothelioma,
especially in merlin-negative cells, it would be interesting to investigate whether modulating RYK expression/
activity might influence mesothelioma cell motility and
adhesion and/or the proliferation and survival of mesothelioma CSCs derived from NF2−/− tumors. Progranulin depletion strongly enhances FAK phosphorylation at
Y397, site critical for FA turnover. Notably, FAK Y397

Page 18 of 21

phosphorylation promotes FA assembly, followed by FAK
Y397 dephosphorylation and FA disassembly, which is
the fundamental step required for cell motility [47, 50, 51,
86]. Indeed, F
 AK−/− fibroblasts had an increased number of FA, reduced FA disassembly and reduced migration [87]. It has been demonstrated that FA disassembly
relies on the targeting of FA by microtubules and on different molecules including dynamin, whose localization
and activity at the site of FA is regulated by FAK [50, 88].
Here we demonstrated that mesothelioma cells with progranulin depletion have altered FA turnover, with slower
and reduced FA disassembly. Thus, the inhibition of FA
disassembly in progranulin-depleted mesothelioma cells
is likely the biochemical mechanism determining the
reduced migratory and invasive abilities of these cells.

Conclusion
Our results point out to a complex progranulin signaling
mechanisms in mesothelioma, where progranulin mediates the activation and cross-talk of multiple RTKs with
key roles in establishing and maintaining mesothelioma
malignant phenotypes, where progranulin signaling is
context-dependent. Our study suggests that blocking
progranulin signaling might represent a viable therapeutic strategy for mesothelioma. However, the efficacy
of potential therapeutic strategies targeting progranulin
might differ depending on mesothelioma subtype and
combinatorial approaches inhibiting homeostatic compensatory mechanisms might be required.
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